Helixbind


HelixBind is developing an innovative diagnostic platform to revolutionize care for bloodstream infections. Its proprietary platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying invasive infections and developing personalized antimicrobial interventions for infected patients. The company aims to improve outcomes, reduce the spread of antimicrobial resistance, and save lives through cutting-edge technology and rapid diagnostics.

Industries

biotechnology
medical
medical-device

Nr. of Employees

small (1-50)

Helixbind

Worcester, Massachusetts, United States, North America


Products

Benchtop rapid diagnostic instrument and disposable sample cassette (sample-to-answer)

An automated, integrated diagnostic system comprising a small benchtop instrument and single-use disposable fluidic cassettes that process a blood specimen and deliver species-level pathogen identification and resistance marker information within a few hours.


Services

Diagnostic platform deployment and integration

On-site deployment of benchtop diagnostic instruments and consumable cassettes, including integration with hospital LIS and user workflow automation.

Clinical validation and study partnerships

Collaborative studies to evaluate assay performance for identifying bloodstream infections and associated clinical utility.

Expertise Areas

  • Direct-from-blood molecular diagnostics
  • Assay and sample-preparation development
  • Integrated microfluidic device engineering
  • Automated sample-to-answer platform engineering
  • Show More (6)

Key Technologies

  • Direct-from-blood molecular detection
  • Artificial/engineered nucleic acid chemistries
  • Integrated microfluidics and disposable cassettes
  • Automated sample-to-answer instrumentation
  • Show More (5)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.